SCHEMBL31291020

SCHEMBL31291020

COC(=O)c1ccc2cccc3c2c1C=C3

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPRC P08575 1/20 0.47
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ MAPT P10636 5/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ PTK2B Q14289 1/20 0.39
▸ NCOA1 Q15788 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NCOA3 Q9Y6Q9 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ CFTR P13569 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15495742 1.00 PTPRC (0.47) PTPRCSLC6A2SLC6A4SLC6A3MAPT
SCHEMBL5379907 0.82 KMT2A (0.42) MAPTMEN1KMT2ATSHRNPSR1
SCHEMBL5371317 0.80 HSD17B10 (0.52) MAPTMEN1KMT2ATSHRALDH1A1
SCHEMBL27901863 0.76 KMT2A (0.36) MAPTMEN1KMT2ATSHRALDH1A1
SCHEMBL13293021 0.76 TSHR (0.53) PTPRCSLC6A2SLC6A4SLC6A3MAPT
SCHEMBL8765365 0.76 KDM4E (0.45) PTPRCMEN1KMT2ATSHRNPSR1
SCHEMBL28757186 0.75 PTPRC (0.38) PTPRCSLC6A2SLC6A4SLC6A3MAPT
SCHEMBL8711975 0.74 ALDH1A1 (0.32) MEN1KMT2ATSHRNPSR1ALDH1A1
SCHEMBL29576400 0.74 KDM4E (0.58) PTPRCSLC6A2SLC6A4SLC6A3MAPT
SCHEMBL68712 0.74 KDM4E (0.58) PTPRCSLC6A2SLC6A4SLC6A3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250044689-A1 MONOMER, POLYMER, CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION, AND RESIST PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-02-06 — — US disclosed
EP-4498160-A1 MONOMER, POLYMER, CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION, AND RESIST PATTERN FORMING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2025-01-29 — — EP disclosed
CN-119371289-A Monomer, polymer, chemically amplified negative resist composition, and resist pattern forming method 信越化学工业株式会社 2025-01-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250044689-A1 MONOMER, POLYMER, CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION, AND RESIST PATTERN FORMING PROCESS PARG, PARN, PCNA PTPRC 2382/4885SLC6A2 4478/4885SLC6A4 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback